Project Grant R21OD034471
- Federal Grant Award Summary Stony Brook University received a $158,500 Project Grant award dated July 22, 2025, under the Trans-NIH Research Support program (CFDA 93.310) from the National Institutes of Health Office of the Director. The grant funds research investigating the mitigative effects of apigenin, a naturally occurring flavonoid, against gastrointestinal acute radiation syndrome (GI-ARS) in mice. The research addresses a critical gap in approved countermeasures for GI-ARS, a...
- Federal Project Grant Award Summary Columbia University's Health Sciences Division received a $164,500 Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), effective August 19, 2025, with completion targeted for July 31, 2027. The award funds the development and validation of human normal tissue patient-derived organoids (NT-PDOs) established from healthy tissue biopsies to serve as a pre-screening...
- Federal Grant Award Summary The Feinstein Institutes for Medical Research received a $167,500 Project Grant (R21) award dated July 3, 2025, from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310). This research initiative aims to develop MSP68, a pentapeptide derived from milk fat globule-epidermal growth factor-factor VIII (MFG-E8), as a novel medical countermeasure to treat gastrointestinal acute radiation syndrome (GI-ARS)...
- Federal Project Grant Award Summary The University of Arkansas for Medical Sciences received a $153,000 Project Grant award from the National Institutes of Health Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) on August 25, 2025, for research on methionine metabolism in acute radiation response in the gastrointestinal tract. The grant supports a two-year investigation through July 31, 2027, examining radiomitigating strategies for gastrointestinal acute...
- Federal Project Grant Award Summary The National Institute of Environmental Health Sciences awarded a $340,383 Project Grant (CFDA 93.113, Environmental Health program) to The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. on September 22, 2025, with completion expected by September 21, 2027. This research initiative investigates the mechanisms of radiation-induced hemolysis in red blood cells (RBCs) following total body irradiation exposure. The project addresses a...
- Federal Project Grant Award Summary New York Blood Center, Inc. received a $170,800 Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), effective July 15, 2025 through June 30, 2027. The award funds research to develop radiation countermeasures that account for sex-dependent differences in radiation response. The research aims to understand the mechanisms underlying sex-specific effects in radiation...
- Federal Grant Award Summary Albany Medical College received a $164,000 Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), effective August 5, 2025, with a completion date of July 31, 2027. The project focuses on developing specialized pro-resolving lipid mediators (SPMs) as systemic radiation countermeasures to address the urgent clinical need for therapies targeting delayed effects of acute...
- The University of Arizona received a Cooperative Agreement award of $583,468 from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), effective September 16, 2025, with completion targeted for August 31, 2030. The award funds the development and optimization of MH01, a novel small-molecule protein ligand interface stabilizer (SPLINTS) designed as a medical countermeasure for mitigating radiation exposure. The therapeutic...
- Federal Project Grant Award Summary The University of Kansas Medical Center Research Institute, Inc. received a $155,000 Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), effective August 25, 2025, with a completion date of July 31, 2027. This award funds research aimed at mitigating gastrointestinal acute radiation syndrome (GI-ARS) through investigation of phosphoglycerate mutase 5 (PGAM5), a...
- This Project Grant award from the National Science Foundation (NSF) Division of Molecular and Cellular Biosciences, under the Biological Sciences program (CFDA 47.074), provides $910,000 over 4 years to Weill Medical College of Cornell University to conduct research on the regulation of DNA repair mechanisms and transcription at telomeres. The research aims to improve understanding of how genetic information is protected at chromosome ends, which is critical for cell and organism health. The...
IDENTIFYING THE RADIOPROTECTIVE POTENTIAL OF RADIATION-RESISTANT FUNGI USING DROSOPHILA - PROJECT SUMMARY: IONIZING RADIATION CAUSES DOUBLE STRAND BREAKS AND DAMAGES THE PROTEIN-BASED MECHANISMS RESPONSIBLE FOR THEIR REPAIR. THIS MAKES MITOTIC CELLS IN THE BONE MARROW, GUT AND REPRODUCTIVE ORGANS HIGHLY SUSCEPTIBLE TO IONIZING RADIATION DAMAGE. IN ADDITION, AS HUMANS AGE, WE BECOME MORE SUSCEPTIBLE TO THE EFFECTS OF RADIATION LIKELY DUE TO INHERENT ACCUMULATED CELLULAR DAMAGE WE ACCRUE OVER TIME. THERE ARE VERY FEW PHARMACEUTICAL COUNTERMEASURES APPROVED FOR MITIGATION OF ACUTE RADIATION DAMAGE, AND NONE ARE EFFECTIVE FOR PROPHYLACTIC INTERVENTION. GIVEN THE USE OF NUCLEAR POWER PLANTS, THE PROLIFERATION OF NUCLEAR ARMS AND INCREASED GLOBAL INTEREST IN SPACE FLIGHT WITH ITS CONCOMITANT COSMIC RAY EXPOSURE, THERE IS A PRESSING NEED TO IDENTIFY MEDICINAL SOURCES OF RADIOPROPHYLACTICS. FUNGI ARE SOURCES OF DIVERSE AND POWERFUL PHARMACEUTICALS, AND MANY STRAINS OF FUNGI ARE REMARKABLY RADIORESISTANT. VARIOUS FUNGI HAVE BEEN FOUND GROWING IN THE HEAVILY IRRADIATED ENVIRONMENTS OF THE CHERNOBYL NUCLEAR POWER PLANT AND THE INTERNATIONAL SPACE STATION. TO MEET THE GROWING NEED FOR RADIOPROPHYLACTICS, WE SEEK TO DETERMINE THE RADIOPROTECTIVE EFFICACY OF DIETARY ADMINISTRATION OF HIGHLY RADIATION-RESISTANT NON- PATHOGENIC FUNGI. DROSOPHILA ARE NATURAL FUNGIVORES. IN ADDITION, DROSOPHILA ARE AN EXCELLENT MODEL SYSTEM IN WHICH TO STUDY THE DAMAGING EFFECT OF RADIATION EXPOSURE ON VARIOUS ORGAN SYSTEMS SINCE THEY SHARE MANY SIMILARITIES WITH VERTEBRATES YET ARE EASILY MANIPULATED WITH SOPHISTICATED GENETICS AND CELL BIOLOGY. WE HYPOTHESIZE THAT CONSUMPTION OF THESE FUNGAL STRAINS WILL INCREASE RESISTANCE TO ACUTE RADIATION DAMAGE THROUGH KNOWN AND UNIDENTIFIED FACTORS. TO DO THIS, WE WILL FEED THREE DROSOPHILA GENOTYPES A PANEL OF HIGHLY RADIORESISTANT FUNGI. IN ADDITION TO WILD TYPE FLIES, WE WILL ALSO TEST WHETHER RADIORESISTANT FUNGI CONFER RADIATION RESISTANCE TO TWO MUTANT DROSOPHILA STRAINS THAT ACCUMULATE OXIDATIVE DAMAGE. TO TEST OUR HYPOTHESIS, WE PROPOSE A SINGLE AIM. WE WILL EXPOSURE THE FLIES TO GAMMA IRRADIATION AND TEST IF THE SELECTED DIETARY FUNGI CONFER RADIOPROTECTION TO LIFESPAN, THE GASTROINTESTINAL TRACT, THE OVARY, AND VARIOUS BIOMOLECULES. WE EXPECT TO FIND A RADIOPROTECTIVE EFFECT OF DIETARY RADIORESISTANT FUNGI AT ONE OR SEVERAL LEVELS OF OUR STUDIES FROM ORGANISMAL TO MOLECULAR. KNOWLEDGE GAINED FROM THIS RESEARCH WILL OPEN THE OPPORTUNITY TO SCREEN HUNDREDS OF FUNGI USING A RELATIVELY SIMPLE METHOD. ONCE PROTECTIVE FUNGAL STRAINS ARE IDENTIFIED, FUTURE STUDIES CAN TEST THEIR EFFECTIVENESS IN VERTEBRATES, AS WELL AS IDENTIFY THE MOLECULES RESPONSIBLE.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $199.5k | 8/7/25 | ||
| Not listed | $239.4k | 7/25/24 |